US FDA warns company that disease-awareness websites are "branded" promotional material
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has informed Novartis that it has reviewed two company-sponsored websites purportedly containing disease-state information and concluded that they had gone beyond disease awareness and appeared to be attempts to improperly promote the company’s product Gleevec (imatinib mesylate)1.